The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
Open accessAbstract
Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called “general tumor markers.” The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Service, F. J., & Natt, N. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6934 · Cited by 168
Cited by
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Deprez, P. H., Moons, L. M. G., OʼToole, D., Gincul, R., Seicean, A., Pimentel-Nunes, P., Fernández-Esparrach, G., Polkowski, M., Vieth, M., Borbath, I., et al. (2022) · Endoscopy · doi:10.1055/a-1751-5742 · Cited by 384
Sampedro-Núñez, M., Serrano-Somavilla, A., Adrados, M., Cameselle-Teijeiro, J. M., Blanco-Carrera, C., Cabezas-Agricola, J. M., Martínez-Hernández, R., Martín-Pérez, E., Muñoz de Nova, J. L., Díaz, J. Á., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36129-1 · Cited by 49
on behalf of, N. I. K. E., Fanciulli, G., Ruggeri, R. M., Grossrubatscher, E., Calzo, F. L., Wood, T. D., Faggiano, A., Isidori, A., & Colao, A. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09547-8 · Cited by 47
Metadata
- Authors
- Oberg, K., Couvelard, A., Delle Fave, G., Gross, D., Grossman, A., Jensen, R. T., Pape, U.-F., Perren, A., Rindi, G., Ruszniewski, P., Scoazec, J.-Y., Welin, S., Wiedenmann, B., Ferone, D., & participants, A. O. A. C. C.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 105
- Issue
- 3
- Pages
- 201-211
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2605284234
- Cited by
- 176
- References
- 1
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. https://app.cochat.ai/papers/10.1159/000472254
- The paper
- Oberg, K., Couvelard, A., Delle Fave, G., Gross, D., Grossman, A., Jensen, R. T., Pape, U.-F., Perren, A., Rindi, G., Ruszniewski, P., Scoazec, J.-Y., Welin, S., Wiedenmann, B., Ferone, D., & participants, A. O. A. C. C. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology. https://doi.org/10.1159/000472254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.